Recurrent Pericarditis: When to Use Colchicine, IL-1 Blockers, and How to Prevent Relapse

Research-informed explainer — last updated April 12, 2026

Pericarditis recurs in up to 30% of patients after an initial episode, and without the right treatment at each stage — NSAIDs plus colchicine initially, then IL-1 blockers for corticosteroid-dependent cases — many patients cycle through painful flares for years. The evidence now supports a clear stepwise approach that prevents most recurrences when followed correctly.

This article draws on research from four cardiologists with expertise in pericardial disease and multimodality cardiac imaging. Paul Cremer, M.D., Associate Professor of Medicine at Northwestern Memorial Hospital, is a leading expert on complicated pericarditis who has published on pericardial effusion management, anakinra for refractory cases, and imaging-guided therapies for pericardial diseases. Paul Schoenhagen, MD, at Cleveland Clinic, has published on constrictive pericarditis etiology and survival after pericardiectomy, and co-authored multimodality imaging recommendations for pericardial disease. Brian Griffin, MD, Head of Cardiovascular Imaging at Cleveland Clinic, published foundational work on distinguishing constrictive pericarditis from restrictive cardiomyopathy — the critical diagnostic challenge in late pericarditis complications. Manesh Patel, M.D., Chief of Cardiology at Duke University Hospital, is an expert in multimodality cardiac imaging whose work on cardiac sarcoidosis and inflammatory cardiomyopathies informs the differential diagnosis workup relevant to pericarditis management.

What is pericarditis and why does it recur?

Pericarditis is inflammation of the pericardium — the two-layered sac surrounding the heart. Most cases in developed countries are idiopathic or viral in origin (presumed viral). Other causes include bacterial infection, autoimmune disease (lupus, rheumatoid arthritis), post-cardiac injury (including post-myocardial infarction and post-surgery), and radiation.

The initial episode typically presents with sharp chest pain that worsens when lying flat and improves when leaning forward, accompanied by a friction rub on auscultation, ECG changes (diffuse ST elevation with PR depression), and elevated inflammatory markers (CRP, ESR). Echocardiography is essential to identify pericardial effusion and assess for tamponade.

Recurrence — defined as a new episode after an initial symptom-free period of at least 4–6 weeks — occurs in 20–30% of patients. Incessant pericarditis (symptoms persisting beyond 4–6 weeks without remission) and chronic pericarditis (lasting more than 3 months) are related but distinct patterns.

The pathophysiology of recurrence appears to involve persistent low-level pericardial inflammation and, in some patients, activation of the NLRP3 inflammasome and IL-1 pathway — the biological target of the most effective rescue therapies.

Step 1: NSAIDs plus colchicine — the evidence-based first line

The cornerstone of acute pericarditis treatment is NSAIDs (ibuprofen or aspirin at anti-inflammatory doses) combined with colchicine. Multiple randomized trials, including the COPE and ICAP trials, demonstrated that adding colchicine to NSAIDs reduces the recurrence rate from approximately 30–35% to about 15% — roughly halving the risk of relapse.

The key principles of acute treatment include:

• Prescribe NSAIDs at full anti-inflammatory doses for 1–2 weeks (longer if needed for symptom resolution)
• Colchicine 0.5 mg twice daily (or 0.5 mg once daily in low-weight patients) for 3 months
• Taper NSAIDs based on symptoms and CRP normalization, not time alone
• Restrict physical activity until symptoms resolve and CRP normalizes — this is critically important and often undertreated; athletes particularly need structured activity restriction

Corticosteroids are effective but associated with significantly higher recurrence rates than NSAIDs plus colchicine and should not be used as first-line therapy for acute pericarditis except in specific situations (pregnancy, NSAID contraindication, autoimmune disease).

A 2016 paper by Cremer and colleagues in the Journal of the American College of Cardiology on complicated pericarditis defines the subset of patients who are at highest risk for complications and need more aggressive management from the outset: those with fever above 38°C, subacute onset, large pericardial effusion, cardiac tamponade, failure to respond to NSAIDs after one week, elevated troponin (indicating myopericarditis), and immunosuppressed state.

Step 2: When recurrence happens — back to basics with added vigilance

For a first recurrence, the approach is to restart NSAIDs at full dose with colchicine extended to 6 months, and to taper more slowly. The most common reason for recurrence is premature discontinuation of anti-inflammatory therapy before CRP has fully normalized.

Pericardial effusion management in recurrent cases is guided by size, symptoms, and hemodynamic impact. A comprehensive 2017 review by Cremer and colleagues in Progress in Cardiovascular Diseases covers the differential diagnosis of pericardial effusions and management options including pericardiocentesis. The 2013 ASE multimodality imaging recommendations co-authored by Schoenhagen provide guidance on how echocardiography, CT, and cardiac MRI should be used in pericardial disease evaluation.

Cardiac MRI is particularly valuable in evaluating recurrent pericarditis: pericardial late gadolinium enhancement (LGE) on CMR confirms active pericardial inflammation even when CRP is normal, helps identify myocardial involvement (myopericarditis), and guides decisions about treatment duration.

Step 3: Corticosteroid-dependent and colchicine-resistant pericarditis — when IL-1 blockade is needed

A subset of patients develop a pattern of dependence on corticosteroids — they cannot taper below a threshold dose without flaring. This is a recognized risk factor for recurrence because corticosteroid withdrawal itself triggers inflammation. For these patients, the NLRP3/IL-1 axis appears to be driving persistent inflammation, and IL-1 blockers offer targeted relief.

The IRAP registry, published in the European Journal of Preventive Cardiology in 2019, with Cremer among the contributing authors, evaluated anakinra (an IL-1 receptor antagonist, administered as daily subcutaneous injections) in 224 patients with corticosteroid-dependent and/or colchicine-resistant recurrent pericarditis across 24 centers. Results: 94.6% of patients achieved complete remission. At 14 months of follow-up, recurrence after stopping anakinra occurred in approximately 35% — still a meaningful improvement over the nearly universal relapse seen with corticosteroid tapering alone.

Rilonacept (an IL-1α/β trap), FDA-approved in 2021 for recurrent pericarditis under the brand name Arcalyst, was the first drug specifically approved for this indication, based on the RHAPSODY trial showing 96% reduction in recurrence risk compared to placebo. Both anakinra and rilonacept are used in patients who have failed adequate trials of NSAIDs plus colchicine, with or without corticosteroids.

The feared complication: constrictive pericarditis

The most serious long-term complication of pericarditis is constrictive pericarditis — a fibrous scarring and thickening of the pericardium that restricts cardiac filling and mimics right heart failure. This occurs in less than 0.5% of idiopathic cases but in higher proportions of patients with bacterial or TB pericarditis.

The diagnostic challenge of distinguishing constrictive pericarditis from restrictive cardiomyopathy (both present with diastolic heart failure and elevated filling pressures) was definitively addressed by Griffin and colleagues in a landmark 1996 paper in the Journal of the American College of Cardiology. Tissue Doppler imaging showing preserved or increased early mitral annular velocity (e') with inspiration-related septal bounce is characteristic of constriction — a pattern not seen in restriction. CT and CMR can confirm pericardial thickening (greater than 4 mm), though constriction can occur without obvious thickening.

When constrictive pericarditis is confirmed and causing significant symptoms, pericardiectomy (surgical removal of the pericardium) is the definitive treatment. Research by Schoenhagen and colleagues published in the Journal of the American College of Cardiology (2004) analyzed 163 pericardiectomy patients and found that etiology strongly predicted survival: idiopathic and post-surgical causes had the best outcomes, while radiation-induced constriction carried the worst prognosis. Overall operative mortality was 6% at experienced centers, but outcomes were significantly better at high-volume institutions.

Questions to ask your doctor

• Was my CRP normal before my NSAIDs were tapered, and was colchicine continued for the full recommended duration?
• Am I restricting physical activity until my CRP is normal and symptoms are gone?
• For my recurrence — should I be evaluated with cardiac MRI to confirm pericardial inflammation?
• If I am corticosteroid-dependent, am I a candidate for anakinra or rilonacept?
• Do I have any signs of constrictive pericarditis that require further imaging?
• What is my underlying cause of pericarditis, and does it change my treatment or monitoring plan?

The bottom line

Most recurrent pericarditis can be controlled with properly dosed and properly tapered NSAIDs plus colchicine for at least 3–6 months, guided by CRP normalization rather than a calendar. For patients with corticosteroid-dependent or colchicine-resistant disease, IL-1 blockers — particularly rilonacept (FDA-approved) and anakinra (widely used off-label) — provide highly effective rescue therapy. Constrictive pericarditis, while uncommon, requires expert multimodality imaging and referral to a high-volume surgical center when intervention is needed.